{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.0","upperLimit":"46.8","value":"38.4"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"30.2","value":"22.6"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.3","upperLimit":"28.6","value":"21.0"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"12.8","value":"7.2"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.9","upperLimit":"22.8","value":"15.87"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"5.7","value":"1.8"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"21.8","value":"14.8"},{"comment":"Median, lower and upper limit not reached due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"17.5","value":"11.0"},{"comment":"Median, lower and upper limit not reached due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"15.1","value":"8.9"},{"comment":"Median, lower and upper limit not reached due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"15.1","value":"8.9"},{"comment":"Median, lower and upper limit not reached due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"60 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"13.7","value":"7.6"},{"comment":"Median, lower and upper limit not reached due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"72 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"12.2","value":"6.1"},{"comment":"Median, lower and upper limit not reached due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"84 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"PFSR was defined as the percentage of participants who did not experience disease progression or death from any cause at a given time point following randomization. Progression was assessed by investigators according to RECIST v1.1. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including on-treatment palliative radiation therapy (RT) of non-target bone lesions or CNS lesions) without a prior reported progression were to be censored at the last evaluable tumor assessment prior to or on initiation of the subsequent anti-cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to specified timepoints, up to 84 months","title":"Progression Free Survival Rate (PFSR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}